These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 8912765)
1. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. McGregor MM; Olliaro P; Wolmarans L; Mabuza B; Bredell M; Felten MK; Fourie PB Am J Respir Crit Care Med; 1996 Nov; 154(5):1462-7. PubMed ID: 8912765 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Ji B; Truffot-Pernot C; Lacroix C; Raviglione MC; O'Brien RJ; Olliaro P; Roscigno G; Grosset J Am Rev Respir Dis; 1993 Dec; 148(6 Pt 1):1541-6. PubMed ID: 8256897 [TBL] [Abstract][Full Text] [Related]
3. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group. Gonzalez-Montaner LJ; Natal S; Yongchaiyud P; Olliaro P Tuber Lung Dis; 1994 Oct; 75(5):341-7. PubMed ID: 7841427 [TBL] [Abstract][Full Text] [Related]
4. Importance of rifampicin in combined daily/intermittent chemotherapy for tuberculosis. Felten MK S Afr Med J; 1989 Jun; 75(11):524-6. PubMed ID: 2727841 [TBL] [Abstract][Full Text] [Related]
5. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Burman W; Benator D; Vernon A; Khan A; Jones B; Silva C; Lahart C; Weis S; King B; Mangura B; Weiner M; El-Sadr W; Am J Respir Crit Care Med; 2006 Feb; 173(3):350-6. PubMed ID: 16109981 [TBL] [Abstract][Full Text] [Related]
6. [The tolerability and therapeutic efficacy of rifabutin in the treatment of pulmonary tuberculosis]. Parola D; Dell'Orso D; Giovagnoli S; Bianconi S; Terzano C Recenti Prog Med; 1999 May; 90(5):254-7. PubMed ID: 10380552 [TBL] [Abstract][Full Text] [Related]
7. [Clinical experience using rifabutin for treating infection with Mycobacterium tuberculosis in elderly Japanese patients]. Morimoto K; Yoshiyama T; Kuse M; Okumura M; Sasaki Y; Yoshimori K; Ogata H; Kurashima A; Kudoh S Kekkaku; 2013 Aug; 88(8):625-8. PubMed ID: 24044166 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients. Kouanda S; Ouedraogo HG; Cisse K; Compaoré TR; Sulis G; Diagbouga S; Roggi A; Tarnagda G; Villani P; Sangare L; Simporé J; Regazzi M; Matteelli A BMC Infect Dis; 2020 Jun; 20(1):449. PubMed ID: 32590942 [TBL] [Abstract][Full Text] [Related]
9. [Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis: (1). A study on the efficacy of short course treatment with the intratracheal and intravenous infection model]. Doi N Kekkaku; 1998 Feb; 73(2):53-64. PubMed ID: 9545697 [TBL] [Abstract][Full Text] [Related]
10. [A new anti-mycobacterial agent, rifabutin]. Kurashima A; Mori T; Tomono Y; Abe S; Nagaoka M; Abe M Kekkaku; 2010 Oct; 85(10):743-56. PubMed ID: 21061564 [TBL] [Abstract][Full Text] [Related]
11. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Wallace RJ; Brown BA; Griffith DE; Girard WM; Murphy DT Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1766-72. PubMed ID: 8665032 [TBL] [Abstract][Full Text] [Related]
12. [A controlled clinical trial of long course chemotherapy regimens containing rifabutin in the treatment of multi-drug resistant pulmonary tuberculosis]. Zhu LZ; Fu Y; Chu NH; Ye ZZ; Xiao HP; Wang W; Yuan SL; Zhang X; Luo YA; Ma LP Zhonghua Jie He He Hu Xi Za Zhi; 2006 Aug; 29(8):520-3. PubMed ID: 17074263 [TBL] [Abstract][Full Text] [Related]
13. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Li J; Munsiff SS; Driver CR; Sackoff J Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767 [TBL] [Abstract][Full Text] [Related]
14. Improved tuberculosis outcomes with daily vs. intermittent rifabutin in HIV-TB coinfected patients in India. Jenks JD; Kumarasamy N; Ezhilarasi C; Poongulali S; Ambrose P; Yepthomi T; Devaraj C; Benson CA Int J Tuberc Lung Dis; 2016 Sep; 20(9):1181-4. PubMed ID: 27510243 [TBL] [Abstract][Full Text] [Related]
15. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study. Matteelli A; Olliaro P; Signorini L; Cadeo G; Scalzini A; Bonazzi L; Caligaris S; Tomasoni L; Tebaldi A; Carosi G Int J Tuberc Lung Dis; 1999 Nov; 3(11):1043-6. PubMed ID: 10587327 [TBL] [Abstract][Full Text] [Related]
16. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398 [TBL] [Abstract][Full Text] [Related]
17. Use of rifabutin in the treatment of pulmonary tuberculosis. Grassi C; Peona V Clin Infect Dis; 1996 Apr; 22 Suppl 1():S50-4. PubMed ID: 8785257 [TBL] [Abstract][Full Text] [Related]
18. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. Naiker S; Connolly C; Wiesner L; Kellerman T; Reddy T; Harries A; McIlleron H; Lienhardt C; Pym A BMC Pharmacol Toxicol; 2014 Nov; 15():61. PubMed ID: 25406657 [TBL] [Abstract][Full Text] [Related]
19. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis. Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119 [TBL] [Abstract][Full Text] [Related]